Research on GLP-1 drugs, specialty therapies and more helps improve affordability in health care

Drug Approvals Monthly Update: August 2024 This monthly update of United States (U.S.) Food and Drug Administration (FDA) approvals provides a review of newly approved specialty drugs, new...

Studies include Prime’s GLP-1 obesity research and a Medicare drug cost predictive model

Studies on GLP-1 drugs, specialty therapies and more help improve affordability in health care

New data reveal sharp growth in Ozempic prescribing across the country, reflecting the rising demand for GLP-1 therapies

As demand for GLP-1a drugs for weight loss has increased, new data provides additional insights about this new class of medications.

Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...

New research suggests the clinical benefits of GLP-1 therapies have yet to translate into near-term medical cost savings

Only about 15% of people who began taking GLP-1 drugs such as Wegovy stuck with them after two years

The 2026 Medical Pharmacy Trend Report: Part 1– Payer Survey reflects Prime Therapeutics’ long standing commitment to delivering trusted, data driven perspectives that shape the industry...